Diffuse Glioma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Fusion
ARAF
ARAF Mutation
BRAF
BRAF Fusion
BRAF Mutation
BRAF V600A
BRAF V600D
BRAF V600E
BRAF V600G
BRAF V600K
BRAF V600M
BRAF V600R
CRKL
CRKL Mutation
Deficient DNA Mismatch Repair (dMMR)
FGFR1
FGFR1 Mutation
FGFR2

FGFR2 Mutation
FGFR3
FGFR3 Mutation
H3F3A
H3F3A Codon 34 Missense
H3F3A Codon 35 Missense
H3F3A K27M
H3F3A K28M
HRAS
HRAS Mutation

IDH1
IDH1 Mutation
IDH2
IDH2 Mutation
KRAS
KRAS Mutation
MAP2K1
MAP2K1 Mutation
MAP2K2
MAP2K2 Mutation

MAP2K4
MAP2K4 Loss
MAP2K4 Mutation
MAP3K1
MAP3K1 Loss
MAP3K1 Mutation
MAPK1
MAPK1 Mutation
MLH1 Deficient Expression
MSH2 Deficient Expression

MSH6 Deficient Expression
MSI-High
MYB
MYB Mutation
MYBL1
MYBL1 Mutation
NF1
NF1 Loss
NF1 Mutation
NF2

NF2 Loss
NF2 Mutation
NRAS
NRAS Mutation
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion

PMS2 Deficient Expression
PTPN1
PTPN1 Mutation
RAF1
RAF1 Mutation
RB1
RB1 Loss
RB1 Mutation
ROS1
ROS1 Fusion

SOS1
SOS1 Mutation
SRC
SRC Mutation

Overview

NCI Definition: A glioma that has diffusely infiltrated the surrounding central nervous system tissues. [1]

Diffuse gliomas most frequently harbor alterations in TP53, PTEN, CDKN2A, IDH1, and EGFR [2].

Most Commonly Altered Genes in Diffuse Glioma

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, IDH1 Mutation, and IDH1 Codon 132 Missense are the most common alterations in diffuse glioma [2].

Top Alterations in Diffuse Glioma

Clinical Trials

View Clinical Trials for Diffuse Glioma

There are 5 clinical trials for diffuse glioma, of which 5 are open and 0 are completed or closed. Of the trials that contain diffuse glioma as an inclusion criterion, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 3 (1 open).

H3F3A, ARAF, and BRAF are the most frequent gene inclusion criteria for diffuse glioma clinical trials [3].

Trials Investigating Diffuse Glioma by Gene and Recruiting Status

Temozolomide, nms-03305293, and onc206 are the most common interventions in diffuse glioma clinical trials.

Drugs Being Investigated in Diffuse Glioma Trials by Recruiting Status

Significant Genes in Diffuse Glioma

APC +

APC is altered in 3.33% of diffuse glioma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARAF +

ARAF is altered in 1.29% of diffuse glioma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF +

BRAF is altered in 3.87% of diffuse glioma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK6 +

CDK6 is altered in 1.38% of diffuse glioma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL +

CRKL is altered in 0.54% of diffuse glioma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CTDNEP1 +

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 +

CTNNB1 is altered in 0.87% of diffuse glioma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X +

DDX3X is altered in 0.34% of diffuse glioma patients [2].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR1 +

FGFR1 is altered in 3.61% of diffuse glioma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 1.6% of diffuse glioma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 +

FGFR3 is altered in 3.21% of diffuse glioma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

GLI2 +

GLI2 is altered in 3.13% of diffuse glioma patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A +

H3F3A is altered in 3.86% of diffuse glioma patients [2].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for diffuse glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse glioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [3].

HRAS +

HRAS is altered in 0.66% of diffuse glioma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 +

IDH1 is altered in 26.4% of diffuse glioma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 +

IDH2 is altered in 2.74% of diffuse glioma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A +

KDM6A is altered in 2.13% of diffuse glioma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C +

KMT2C is altered in 3.51% of diffuse glioma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D +

KMT2D is altered in 7.96% of diffuse glioma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS +

KRAS is altered in 1.99% of diffuse glioma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

LRP1B +

LRP1B is altered in 3.04% of diffuse glioma patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K1 +

MAP2K1 is altered in 0.97% of diffuse glioma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 +

MAP2K2 is altered in 0.88% of diffuse glioma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 +

MAP2K4 is altered in 0.93% of diffuse glioma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 +

MAP3K1 is altered in 2.82% of diffuse glioma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 +

MAPK1 is altered in 0.53% of diffuse glioma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 +

MDM4 is altered in 4.06% of diffuse glioma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYB +

MYB is altered in 0.58% of diffuse glioma patients [2].

MYB is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 +

MYBL1 is altered in 1.41% of diffuse glioma patients [2].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC +

MYC is altered in 1.62% of diffuse glioma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL +

MYCL is altered in 1.04% of diffuse glioma patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN +

MYCN is altered in 2.1% of diffuse glioma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 +

NF1 is altered in 16.09% of diffuse glioma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 +

NF2 is altered in 1.37% of diffuse glioma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is altered in 0.95% of diffuse glioma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

OTX2 +

OTX2 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D +

PPM1D is altered in 2.19% of diffuse glioma patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 +

PTCH1 is altered in 3.4% of diffuse glioma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN +

PTEN is altered in 26.87% of diffuse glioma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTPN1 +

PTPN1 is altered in 0.61% of diffuse glioma patients [2].

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PVT1 +

PVT1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 +

RAF1 is altered in 1.12% of diffuse glioma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RELA +

RELA is altered in 0.87% of diffuse glioma patients [2].

RELA is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH +

SHH is altered in 0.54% of diffuse glioma patients [2].

SHH is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 +

SMARCA4 is altered in 3.85% of diffuse glioma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO +

SMO is altered in 1.96% of diffuse glioma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP +

SNCAIP is altered in 2.21% of diffuse glioma patients [2].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SOS1 +

SOS1 is altered in 2.57% of diffuse glioma patients [2].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC +

SRC is altered in 0.84% of diffuse glioma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SUFU +

SUFU is altered in 1.31% of diffuse glioma patients [2].

SUFU is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT +

TERT is altered in 4.05% of diffuse glioma patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 +

TP53 is altered in 37.92% of diffuse glioma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 +

YAP1 is altered in 2.53% of diffuse glioma patients [2].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 +

ZMYM3 is altered in 2.49% of diffuse glioma patients [2].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

Disease Details

Synonyms

Diffuse Glioma WHO Grade 2, Diffuse glioma WHO Grade II

Parent(s)

Glioma

Children

Glioblastoma, Diffuse Astrocytoma, Diffuse Glioma, NOS, Anaplastic Astrocytoma, Mixed Glioma, Gliomatosis Cerebri, Diffuse Intrinsic Pontine Glioma, Oligodendroglioma, Diffuse Midline Glioma, H3 K27M-Mutant, and Anaplastic Oligodendroglioma

OncoTree Name

Diffuse Glioma

OncoTree Code

DIFG

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Diffuse Glioma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Diffuse Glioma

Disease Details

References

About

Molecular Medicine

Content Types